CLEAR-CMV: Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients (clinicaltrials.gov) - Feb 18, 2026 - P4 | N=40 | Recruiting | Sponsor: University Health Network, Toronto | Not yet recruiting ➔ Recruiting
Enrollment open • Cytomegalovirus Infection • Infectious Disease • Respiratory Diseases • Transplantation
|